China regulator to refine insurance capital rules for early-stage, hard-tech investment

The signal here is regulatory, not market: Beijing is adjusting the capital treatment of insurance money so it can flow toward early-stage and hard-tech ventures, a segment where long-duration domestic capital has historically been scarce. Insurance funds are the largest pool of patient institutional capital in China, so even incremental rule changes matter more for the venture funding pipeline than for listed asset prices. What is worth watching is whether the refinement translates into actual deployment into early-stage deals, or remains a policy intention without allocation.